| 4802 |
Centers for Disease Control and Prevention |
Html |
en |
GBS Prevention in Newborns - Group B Strep |
Group B Strep (GBS) Preventing early and late onset GBS. Includes alternative prevention strategies |
| sterile swab | 0.207296 |
| disease | 0.436095 |
| bacteria | 0.811506 |
| important ways | 0.206216 |
| baby develop group | 0.266824 |
| late-onset disease | 0.247308 |
| early-onset group | 0.204935 |
| babies | 0.200753 |
| Birth canal washes | 0.256178 |
| labor | 0.346878 |
|
| pregnant women | 0.682 |
| current pregnancy | 0.269105 |
| severe allergic reaction | 0.254179 |
| positive antibiotics | 0.239493 |
| early-onset disease | 0.305599 |
| pregnant woman | 0.275816 |
| baby | 0.316088 |
| strep disease | 0.363702 |
| antibiotics | 0.546999 |
|
CLICK HERE |
| 6252 |
Centers for Disease Control and Prevention |
Html |
en |
Who Should Get Vaccinated Against Influenza |
Guidelines for Flu Vaccination from CDC. Everyone older than 6 months is recommended for flu vaccination with rare exception. |
| priority group | 0.289814 |
| Household contacts | 0.289768 |
| health care provider | 0.36745 |
| pregnant women | 0.302973 |
| particular emphasis | 0.29445 |
| children | 0.267417 |
| talk | 0.274579 |
| severe influenza illness | 0.43693 |
| influenza vaccine | 0.774264 |
| metabolic disorders | 0.296125 |
| chronic medical conditions | 0.362682 |
| Different flu shots | 0.527648 |
| severe paralyzing illness | 0.398244 |
| 2016-2017 season | 0.309813 |
| vaccine supply | 0.43201 |
| high risk | 0.303965 |
| Guillain-Barré Syndrome | 0.300308 |
| different ages | 0.30328 |
| Considerations Regarding Egg | 0.581495 |
| severe egg allergies | 0.45167 |
| GBS history | 0.314379 |
| severe allergic conditions | 0.388679 |
| chronic health conditions | 0.384822 |
| following people | 0.305617 |
| age-appropriate influenza vaccine | 0.566726 |
|
| adults | 0.244604 |
| flu vaccine | 0.949731 |
| flu complications | 0.445511 |
| life-threatening allergies | 0.33676 |
| flu shots | 0.553714 |
| ingredients | 0.238646 |
| annual flu vaccination | 0.623254 |
| Special Considerations Regarding | 0.561089 |
| spray flu vaccine | 0.719563 |
| health care | 0.394268 |
| medical setting | 0.292241 |
| higher risk | 0.287143 |
| influenza season | 0.348275 |
| recombinant influenza vaccine | 0.640945 |
| Regarding Egg Allergy | 0.581578 |
| vaccination efforts | 0.340697 |
| rare exception | 0.317895 |
| people | 0.456743 |
| injectable flu | 0.473269 |
| doctor | 0.313201 |
| flu shot | 0.541434 |
| egg allergies | 0.685535 |
| information | 0.23737 |
| RIV | 0.229561 |
|
CLICK HERE |
| 7192 |
Centers for Disease Control and Prevention |
Html |
en |
Human Exposures to Marine Brucella Isolated from a Harbor Porpoise - Maine, 2012 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| risk assessment | 0.530541 |
| safe work practices | 0.594133 |
| Various Brucella species | 0.645241 |
| human cases | 0.597807 |
| Brucella exposure | 0.704693 |
| harbor porpoise | 0.54957 |
| stranded marine mammals | 0.549062 |
| Brucella pinnepedialis | 0.609255 |
| Disease Control | 0.65711 |
| potential occupational exposures | 0.565488 |
| Brucella exposures | 0.609633 |
| potential laboratory exposures | 0.571021 |
| Zoonotic Infectious Diseases | 0.626083 |
| daily fever checks | 0.768435 |
| animal diagnostic laboratory | 0.53337 |
| personal protective equipment | 0.615747 |
| regular intervals | 0.53225 |
| Maine CDC | 0.741683 |
| marine mammal Brucella | 0.669627 |
| self-administered daily fever | 0.63437 |
| Antimicrobial postexposure prophylaxis | 0.54839 |
| antimicrobial prophylaxis | 0.624037 |
| severe infections | 0.594745 |
| persons | 0.583009 |
| southern maine | 0.550901 |
|
| Brucella species | 0.929643 |
| acute febrile illness | 0.644149 |
| Brucella organisms | 0.604392 |
| animal necropsy facilities | 0.573696 |
| high risk | 0.684947 |
| necropsy room | 0.569553 |
| Maine Center | 0.645833 |
| Brucella ceti | 0.615733 |
| aerosol-generating procedures | 0.57847 |
| human infection | 0.539588 |
| Human Svcs | 0.540877 |
| Brucella serologic monitoring | 0.661176 |
| physical weakness | 0.607658 |
| Maine Dept | 0.5321 |
| immediate 3-week course | 0.534153 |
| respiratory protection | 0.599463 |
| marine mammal facility | 0.552121 |
| Brucella antibodies | 0.626612 |
| faculty member | 0.531175 |
| marine mammals | 0.957929 |
| 3-week course | 0.590942 |
| positive Brucella culture | 0.806085 |
| community volunteer | 0.531113 |
| brucellosis | 0.567007 |
|
CLICK HERE |
| 8325 |
Centers for Disease Control and Prevention |
Html |
en |
Prevention Strategies - Youth Violence |
null |
| health education | 0.282664 |
| research youth violence | 0.388634 |
| lasting harmful effects | 0.277939 |
| National Centers | 0.265764 |
| mental health | 0.2902 |
| local prevention approaches | 0.285188 |
| Healthy Youth Development | 0.3327 |
| Effective Health Education | 0.27877 |
| prevention tools | 0.259684 |
| evidence-based approaches | 0.249289 |
| student health | 0.246501 |
| violence outcomes | 0.350487 |
| local communities | 0.241918 |
| violence prevention approaches | 0.44923 |
| effective strategies | 0.243298 |
| Effective prevention strategies | 0.300348 |
| key risk factors | 0.269022 |
| local community partners | 0.268319 |
| evidence-based strategies | 0.279989 |
| National Health Education | 0.280789 |
| youth violence prevention | 0.835615 |
| healthy youth behavior | 0.292402 |
| prevention programs | 0.261531 |
| evidence-based youth violence | 0.425407 |
|
| Strategy Selector Tool | 0.327927 |
| unique multidisciplinary approach | 0.262185 |
| community violence | 0.347063 |
| Health Curriculum Analysis | 0.276806 |
| community-based organizations results | 0.264529 |
| Youth violence prevention—one | 0.420532 |
| Community Health Partnerships | 0.282009 |
| Public Health Impact | 0.278585 |
| prevention efforts | 0.2823 |
| public health approach | 0.333719 |
| youth violence | 0.966485 |
| substance abuse | 0.291963 |
| public health | 0.344463 |
| School Health Index | 0.276477 |
| national initiative | 0.271913 |
| health education curricula | 0.277906 |
| Mental Health Services | 0.283735 |
| evidence-based programs | 0.282373 |
| promising strategies | 0.243097 |
| Community Preventive Services | 0.277326 |
| community youth violence | 0.404619 |
| prevention goals | 0.253934 |
| Community Guide | 0.269318 |
| analyze surveillance data | 0.259849 |
|
CLICK HERE |
| 8773 |
Centers for Disease Control and Prevention |
Html |
en |
Notifiable Diseases and Mortality Tables - May 10, 2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| H. influenzae | 0.385129 |
| National Center | 0.301583 |
| cases | 0.436533 |
| CDC | 0.294622 |
| novel influenza | 0.643924 |
| Total case counts | 0.467161 |
| pandemic influenza | 0.951943 |
| measles cases | 0.342141 |
| ** Data | 0.347558 |
|
| Cumulative total E. | 0.475127 |
| Influenza Division | 0.442359 |
| 2009 pandemic | 0.765397 |
| probable cases | 0.328045 |
| Respiratory Diseases | 0.308075 |
| rubella cases | 0.31017 |
| human infection | 0.329997 |
| influenza A virus | 0.477823 |
|
CLICK HERE |
| 11356 |
Centers for Disease Control and Prevention |
Html |
en |
Interim Guidance for Specimen Collection, Transport, Testing, and Submission for Patients with Suspected Infection with Ebola Virus Disease |
null |
| sealable specimen container | 0.444805 |
| potential Ebola virus | 0.61478 |
| Ebola infection | 0.460971 |
| Ebola virus exposure | 0.612414 |
| CDC Form | 0.372781 |
| ebola virus | 0.990656 |
| public health authorities | 0.437395 |
| state health officials | 0.382686 |
| Pathogens Branch specimen | 0.377481 |
| final testing destination | 0.37449 |
| site-specific risk assessment | 0.430051 |
| Ebola Zaire RNA | 0.476561 |
| outer shipping package | 0.425262 |
| LRN laboratories | 0.451332 |
| public health decisions | 0.373321 |
| personal protective equipment | 0.43123 |
| CDC Ebola response | 0.558322 |
| ebola virus disease | 0.770857 |
| body fluids | 0.398406 |
| presumptive positive Ebola | 0.499878 |
| secondary container | 0.403318 |
| clinical laboratories | 0.406557 |
| u.s. laboratories | 0.38028 |
| state public health | 0.439158 |
| aliquot specimens | 0.376796 |
|
| Real-time PCR testing | 0.374342 |
| confirmatory Ebola testing | 0.499283 |
| patient specimens | 0.445315 |
| CDC infection control | 0.412556 |
| Ebola virus testing | 0.584466 |
| Ebola virus infection | 0.582489 |
| United States | 0.465572 |
| vacuum specimen delivery | 0.373607 |
| basic triple packaging | 0.426076 |
| local health department | 0.41895 |
| primary collection container | 0.376736 |
| Presumptive Ebola testing | 0.500607 |
| Hazardous Materials Regulations | 0.423912 |
| primary container | 0.374125 |
| Routine Clinical Specimens | 0.430936 |
| collection tubes | 0.389594 |
| CDC laboratories | 0.384681 |
| specimens | 0.511827 |
| Interim Guidance | 0.378792 |
| Bloodborne Pathogens Standard | 0.430346 |
| Concern About Ebola | 0.475786 |
| guidance | 0.381362 |
| u.s. hospitals | 0.396686 |
| infectious substances | 0.390962 |
|
CLICK HERE |
| 11478 |
Centers for Disease Control and Prevention |
Html |
en |
NCIRD | DBD Bulletin Winter 2012 | Quarter 1 News |
Division of Bacterial Diseases Bulletin Winter |
| Statistics Office | 0.615364 |
| international locations | 0.614974 |
| primary series recommendation | 0.749926 |
| invasive meningococcal disease | 0.829593 |
| lab trainings | 0.623102 |
| booster schedule | 0.63755 |
| AVA manufacturer | 0.672742 |
| local adverse events | 0.721212 |
| DBD staff | 0.623503 |
| Iguacu Falls | 0.623787 |
| Immunization Practices | 0.759105 |
| Advisory Committee | 0.744974 |
| Claire von Mollendorf | 0.729787 |
| Meningococcal Booster Dose | 0.91119 |
| meningococcal conjugate vaccine | 0.910157 |
| significant cost reduction | 0.71694 |
| additional reductions | 0.619718 |
| HIV status | 0.6194 |
| successful culmination | 0.62426 |
| anthrax vaccine | 0.859517 |
| CDC program | 0.639463 |
| GERMS surveillance | 0.624217 |
| Microbial Pathogenesis | 0.616065 |
| historical reasons | 0.6343 |
|
| Amanda Cohn | 0.637904 |
| preventive steps | 0.620949 |
| Anthrax Vaccine Research | 0.824029 |
| Brian Plikaytis | 0.615472 |
| Adult Recommendation | 0.637381 |
| FDA approval | 0.741811 |
| Kathleen Dooling | 0.635965 |
| Pneumococcal Diseases | 0.621555 |
| original licensed schedule | 0.726341 |
| RDB staff | 0.619493 |
| meningococcal capsular group | 0.814466 |
| Leonard Mayer | 0.622574 |
| Gloria Carvalho | 0.61457 |
| Burkina Faso | 0.623241 |
| Medscape video | 0.641345 |
| Elizabeth Zell | 0.626157 |
| 3-dose primary series | 0.928448 |
| Respiratory Diseases | 0.629865 |
| Infectious Diseases | 0.62891 |
| South Africa | 0.625612 |
| Central African Republic | 0.70838 |
| Tdap Vote | 0.617288 |
| single dose | 0.658523 |
|
CLICK HERE |
| 11816 |
Centers for Disease Control and Prevention |
Html |
en |
FAQ: Types of Influenza Vaccine |
Frequently Asked Questions (FAQ) about types of influenza vaccines - CDC |
| Influenza Diagnostic Testing | 0.495776 |
| cell-based flu vaccines | 0.722911 |
| Flu Illness | 0.565754 |
| Flu Viruses | 0.592769 |
| flu vaccines | 0.794192 |
| Prevent Flu | 0.600363 |
| intradermal flu vaccine | 0.672648 |
| Influenza Testing Results | 0.518929 |
| Flu Good Health | 0.59139 |
| Influenza Viruses | 0.519772 |
| Seasonal Influenza Vaccine | 0.775171 |
| Quadrivalent Influenza Vaccine | 0.663023 |
| Intradermal Influenza | 0.497177 |
| Flu Adults | 0.573154 |
| Flu Activity | 0.565245 |
| Influenza Pandemic Virus | 0.505917 |
| (Flu) | 0.741196 |
| Influenza Types | 0.496636 |
| ) Vaccination | 0.673278 |
| Influenza Vaccines | 0.546767 |
| United States Flu | 0.582153 |
| Vaccine Safety Vaccine | 0.606749 |
| Influenza Viruses Types | 0.519409 |
| FLUADâ„¢ Flu Vaccine | 0.666915 |
| Seasonal Flu Shot | 0.578743 |
|
| Flublok Seasonal Influenza | 0.561891 |
| Vaccination Flu Vaccination | 0.631473 |
| High-Dose Seasonal Influenza | 0.565276 |
| Weekly U.S. Influenza | 0.49653 |
| Flu Antiviral Drugs | 0.693024 |
| flu vaccine | 0.934894 |
| CDC International Flu | 0.579593 |
| Prevent Flu Preventive | 0.585715 |
| Seasonal Flu | 0.600694 |
| Flu Vaccine Recommendation | 0.688594 |
| Flu Treatment | 0.57653 |
| Influenza Vaccine | 0.837294 |
| Influenza Vaccination Clinic | 0.517645 |
| Flu News | 0.540013 |
| Flu Complications | 0.555927 |
| Flu Season Flu | 0.850452 |
| Diagnosis Flu Symptoms | 0.586793 |
| Flu Vaccine Safety | 0.73337 |
| Flu Season Current | 0.599409 |
| dose flu vaccine | 0.669756 |
| Flu Vaccines Work | 0.626108 |
| Influenza Vaccine Doses | 0.618665 |
| Past Flu Seasons | 0.588021 |
| Influenza 2015-2016 Season | 0.513133 |
|
CLICK HERE |
| 12207 |
Centers for Disease Control and Prevention |
Html |
null |
Vaccines: Polio |
Polio vaccine info for parents, public, and healthcare professionals |
|
|
CLICK HERE |
| 16304 |
Centers for Disease Control and Prevention |
Html |
en |
FastStats - Influenza |
null |
| figure | 0.33923 |
| Percent | 0.595145 |
| Final Data | 0.453616 |
| adults | 0.437766 |
| National Health Interview | 0.613027 |
| influenza vaccination | 0.920392 |
| Source | 0.372404 |
| population | 0.340197 |
|
| Survey | 0.338154 |
| PDF | 0.371189 |
| Number | 0.339222 |
| MB | 0.391235 |
| children | 0.345699 |
| data table | 0.455779 |
| Early release | 0.477337 |
| deaths | 0.444907 |
|
CLICK HERE |